Major shareholder announcement


Copenhagen, 23 May 2016 – Zealand informs that pursuant to Section 29 of the Danish Securities Act, cf. Executive order no. 1256 of 4 November 2015 on major shareholders and the Danish Companies Act section 55, cf. section 56, the company has on 20 May 2016 received a major shareholder announcement from Sunstone Capital A/S, Lautrupsgade 7, 5., 2100 Copenhagen (CVR-no. 30 57 35 28).

Sunstone Capital A/S has announced to Zealand that Sunstone LSV Management A/S, Lautrupsgade 7, 5., 2100 Copenhagen (CVR-no. 33 85 91 98) has assumed the management of the following funds from Sunstone Capital A/S; P/S Sunstone Biomedicinsk Venture III, K/S Sunstone Biomedical Ventures Annex I, K/S Sunstone Biomedical Ventures Annex II, K/S Sunstone Biomedical Ventures Annex III and Sunstone Life Science Ventures Fund I K/S (the "Funds").

Sunstone Capital A/S no longer act as management company for the Funds and Sunstone LSV Management A/S manages and may exercise voting rights on 5,261,076 shares, corresponding to 21,5% of the total voting rights in Zealand Pharma A/S.


Attachments

18-16_0523 Company Announcement - Major Shareholder announcement (Sunstone LSV Management) - ENG_FINAL.pdf